Evidence-based review of statin use in patients with HIV on antiretroviral therapy

• Main Authors: Daniel B. Chastain, Kayla R. Stover, Daniel M. Riche
• Format: Article
• Language: English
• Published: Elsevier 2017-06-01
• Series: Journal of Clinical & Translational Endocrinology
• Subjects: Antiretroviral therapy; HIV; Statins; Lipids; CVD
• Online Access: http://www.sciencedirect.com/science/article/pii/S2214623717300145

Introduction: As a result of improved safe and effective therapeutic options for human immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading to new challenges (e.g., management of chronic diseases). Some chronic diseases (e.g., cardiovascular disease [CVD]), are up to two times more prevalent in patients with HIV. Statins are a mainstay of therapy for prevention of CVD; but, clinicians should be aware that not all statins are appropriate for use in the HIV population, especially those receiving antiretroviral therapy (ART). The purpose of this article is to review the pharmacokinetic and clinical data for statin therapy in HIV-infected patients receiving ART. Methods: A systematic literature search using PubMed and MEDLINE databases was performed using each statin drug name combined with HIV, pharmacokinetics, AIDS, and/or human immunodeficiency virus. English language trials published from 1946 to November 2016 were considered, and results were limited to clinical efficacy trials. Results: In general, atorvastatin and pravastatin are safe and effective for patients treated with protease-inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor-based ART. Rosuvastatin is generally considered safe if started at a low dose, but should be avoided if possible in patients receiving PI-based ART. Pitavastatin has limited supporting evidence, but appears safe for use based on its pharmacokinetic properties and low number of drug interactions. Fluvastatin, lovastatin, and simvastatin should be avoided in patients receiving ART due to drug interactions, adverse events, and/or limited clinical data. Conclusion: Clinicians need to be familiar with the intricacies of statin selection for the prevention of CVD in patients with HIV on ART.